Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC).

Trial Profile

Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC).

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 07 Jun 2016

At a glance

  • Drugs Doxorubicin (Primary) ; Sorafenib (Primary)
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2016 Results assessing efficacy and safety, presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
    • 10 Feb 2013 New source identified and integrated (Robert H. Lurie Comprehensive Cancer Center, Northwestern University: CALGB80802).
    • 19 Nov 2012 Planned end date changed from 1 Sep 2011 to 1 Jun 2017 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top